Flawed studies linking hormone therapy to breast cancer made doctors reluctant to prescribe it for menopause relief – especially for breast cancer survivors
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial